tradmap

CTKB Earnings Cytek Biosciences, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$0 $0 $0 $0 2020 2021 2022 2023
EPS
Revenue (annual)
$0 $101M $201M 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$67M -$24M $19M $0 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$0 $0 $0 $0 Q2 '20 Q3 '20 Q1 '21 Q2 '21 Q3 '21 Q1 '22 Q2 '22 Q3 '22
EPS
Revenue (quarterly)
$0 $31M $62M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$19M -$9M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–12 of 12
FY 20232023-12-31-0.092024-03-1310-K
FY 20232022-12-310.022024-03-1310-K
Q3 20222022-09-30-0.012022-11-0910-Q
Q2 20222022-06-30-0.022022-08-1010-Q
Q1 20222022-03-310.022022-05-1210-Q
FY 20232021-12-310.002024-03-1310-K
Q3 20222021-09-300.002022-11-0910-Q
Q2 20222021-06-300.002022-08-1010-Q
Q1 20222021-03-310.002022-05-1210-Q
FY 20222020-12-310.102023-03-0110-K
Q3 20212020-09-300.092021-11-1210-Q
Q2 20212020-06-300.042021-09-0310-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.